Liver Cancer Diagnostics Global Market Report 2025

Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.

Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The liver cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $9.69 billion in 2024 to $10.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to biopsy techniques and histopathology, development of biomarker detection, evolution of screening programs, advances in genetic testing, improvements in liver imaging modalities.

The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $13.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to regulatory changes and standardization, growing importance of imaging modalities, development of next-generation sequencing, expanded screening programs and awareness, rising demand for biomarker-based testing. Major trends in the forecast period include rise in incidence and prevalence, advancements in imaging technologies, focus on non-invasive diagnostics, precision medicine and personalized diagnostics, integration of artificial intelligence (AI).

The forecast of 7.4% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for alpha-fetoprotein enzyme-linked immunosorbent assay (AFP ELISA) test kits and contrast-enhanced ultrasound probes, sourced from key regions such as Ireland and Brazil, which could lead to delayed hepatocellular carcinoma detection and higher diagnostic expenses.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.

The growing prevalence of hepatitis B is anticipated to further boost the liver cancer diagnostics market. Hepatitis B, a viral infection affecting the liver, can lead to both acute and chronic conditions. Regular monitoring is essential for individuals with chronic hepatitis B to assess liver health and detect signs of liver damage or cancer. According to the Centers for Disease Control and Prevention, approximately 296 million people, including over 6 million children under the age of 5, are affected by hepatitis B. This growing prevalence of hepatitis B is a significant driver for the expansion of the liver cancer diagnostics market.

Key companies in the liver cancer diagnostics market are creating advanced biomarker-based assays and algorithms to enhance diagnostic accuracy and facilitate early detection. Biomarker-based assays and algorithms are diagnostic tools that employ specific biological markers to identify diseases, offering more precise and efficient diagnostic capabilities. For example, in November 2023, Roche Diagnostics, a U.S.-based biotech corporation, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving early liver cancer detection in high-risk patients. Meanwhile, the Elecsys GAAD algorithm combines various diagnostic markers, including PIVKA-II and AFP, to enhance diagnostic accuracy and streamline decision-making in liver cancer detection.

In April 2023, Integrated DNA Technologies, a U.S.-based biotechnology company, acquired Archer NGS research assays for an undisclosed sum. This acquisition was intended to strengthen Integrated DNA Technologies' portfolio in next-generation sequencing (NGS), with a focus on expanding its research capabilities and enhancing assay development for genomic research. Archer, Inc. is recognized as a U.S. provider of diagnostic solutions for liver cancer.

In December 2022, Fujifilm Holdings Corporation acquired Inspirata, an oncology informatics and healthcare IT solutions provider, for an undisclosed amount. The acquisition included Dynamyx digital pathology technology and involved the integration of Inspirata's staff and clients into Fujifilm. This strategic move allows Fujifilm to expand its Synapse Enterprise Imaging portfolio, incorporating pathology data and images into electronic medical record systems to streamline cancer patient treatment and support care teams.

Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liver cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatoblastoma; Other Types
• 2) By Screening: Laboratory Testing; Imaging; Endoscopy; Biopsy; Other Screenings
• 3) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
• 4) By End Use: Hospitals And Diagnostic Laboratories; Academic And Research Institutes; Pharmaceutical And CRO Laboratories
• Subsegments:
• 1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma; Advanced-Stage Hepatocellular Carcinoma
• 2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma
• 3) By Hepatoblastoma: Pure Hepatoblastoma; Mixed Hepatoblastoma
• 4) Other Types: Secondary Liver Cancer; Fibrolamellar Carcinoma
• Companies Mentioned: Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Qiagen NV; Thermo Fisher Scientific Inc.; Siemens Healthineers; Illumina Inc.; Koninklijke Philips NV; Epigenomics AG; Digna Biotech SL; Biocept Inc.; Danaher Corporation; Foundation Medicine Inc.; Agilent Technologies Inc.; Genemed Biotechnologies Inc.; Merck KGaA; Fujifilm Medical Systems USA Inc.; GE Healthcare; Advanced Cell Diagnostics Inc.; Oxford Gene Technology; Leica Biosystems Nussloch GmbH; Exiqon A/S; BioGenex Laboratories Inc.; OncoCyte Corporation; Guardant Health Inc.; Exact Sciences Corporation; Grail Inc.; Freenome Holdings Inc.; Natera Inc.; Personal Genome Diagnostics Inc.; Thrive Earlier Detection Corp
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.